Key Points
- To delineate the vasoconstriction-volume model of essential hypertension and evaluate the physiological rationale for combining converting enzyme inhibitors with long-acting calcium channel blockers.
- Synthesized mechanistic, epidemiological, and clinical trial evidence evaluating plasma renin activity as a biomarker for vascular risk and antihypertensive drug selection.
- Assessed hemodynamic and hormonal interactions between antirenin agents and antisodium-volume therapies across diverse hypertensive patient subsets.
- Plasma renin activity stratification identifies medium- or high-renin states in approximately 70% of essential hypertensive patients, identifying individuals at elevated risk for heart attack and stroke who respond selectively to antirenin agents.
- Antirenin monotherapy achieves full blood pressure normalization in roughly 40% of patients, whereas combination therapy targeting both renin and volume mechanisms controls hypertension in 70% to 90% of individuals.
- Combining a converting enzyme inhibitor with a long-acting dihydropyridine calcium channel blocker mitigates dihydropyridine-induced reflex tachycardia and peripheral edema while avoiding diuretic-induced hypokalemia and glucose intolerance.
Structured PICO
PPopulationPatients with essential hypertension
IInterventionCombination antihypertensive therapy using an antirenin agent (converting enzyme inhibitor) with a long-acting calcium channel blocker
Baseline plasma renin activity can guide individualized antihypertensive therapy, and combining a converting enzyme inhibitor with a calcium channel blocker offers a physiologically sound approach to maximize efficacy and reduce side effects.